Ehouse Global, Inc. (EHOS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEhouse Global, Inc. (EHOS) trades at $0.00001. Ehouse Global, Inc. focuses on developing, producing, and selling liquid supplements, including vitamins, minerals, and sports nutrition products. The company operates in the competitive healthcare and biotechnology sectors. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for EHOS: EHOS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Ehouse Global, Inc. (EHOS) Healthcare & Pipeline Overview
Ehouse Global, Inc., founded in 2003, develops and distributes liquid supplements, including vitamins, minerals, and sports nutrition products. Operating within the biotechnology sector, the company caters to the diet and wellness market, facing competition from established players and evolving consumer preferences.
What Is the Investment Thesis for EHOS?
Ehouse Global, Inc. presents a speculative investment opportunity within the biotechnology and supplement industry. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance requires careful scrutiny. Potential investors may want to evaluate the company's limited operating scale, reflected in its small employee base of two, and the competitive landscape of the supplement market. Growth catalysts may include successful product innovation and expansion into new distribution channels. However, the company's OTC listing and negative beta of -7.57 indicate higher risk and volatility. A thorough due diligence process is essential to assess the company's long-term viability and growth potential.
Based on FMP financials and quantitative analysis
EHOS Key Highlights
Market capitalization of $0.00B, indicating a micro-cap company.
- Negative P/E ratio of -0.00, suggesting the company is not currently profitable.
- Beta of -7.57, indicating a high degree of volatility and inverse correlation to the market.
- Focus on liquid supplements, a niche market within the broader supplement industry.
- Small employee base of 2, reflecting a limited operational scale.
Who Are EHOS's Competitors?
EHOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EHOS's Key Strengths?
Focus on liquid supplements, a niche market.
- Established brand reputation.
- Proprietary formulations.
- Experienced leadership.
What Are EHOS's Weaknesses?
Small employee base and limited resources.
- Dependence on a limited product line.
- Limited brand awareness compared to larger competitors.
- OTC listing indicates higher risk.
What Are the Key Risks for EHOS?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established supplement manufacturers could erode market share.
- Changing consumer preferences and trends may impact demand for liquid supplements.
- Regulatory scrutiny and compliance requirements could increase operating costs.
- Limited financial resources may hinder growth initiatives.
- OTC listing increases risk due to limited disclosure and liquidity.
What Are EHOS's Competitive Advantages?
- Proprietary liquid supplement formulations.
- Established brand reputation within the niche market.
- Strong relationships with key retailers and distributors.
- Focus on innovation and product development.
What Does EHOS Do?
Ehouse Global, Inc., established in 2003 by Scott Corlett and Edward J. Peplinski, is a biotechnology company focused on the development, production, and sale of liquid supplements. Headquartered in San Diego, California, the company offers a range of products, including vitamins, minerals, sports nutrition supplements, and diet and wellness products. These supplements are designed to cater to health-conscious consumers seeking convenient and effective ways to enhance their nutritional intake. Since its inception, Ehouse Global has aimed to provide accessible and innovative health solutions through its liquid supplement formulations. The company's products are marketed towards individuals interested in improving their overall health, athletic performance, or managing specific dietary needs. The liquid format allows for easy consumption and potentially faster absorption compared to traditional pill or capsule forms. Ehouse Global operates in a competitive market, facing competition from both large, established supplement manufacturers and smaller, niche brands. The company's success depends on its ability to differentiate its products through unique formulations, effective marketing, and strong distribution channels. As of 2026, the company is managed by Jonathan Smith and employs a small team of two individuals.
What Products and Services Does EHOS Offer?
- Develops liquid supplements containing vitamins and minerals.
- Produces sports nutrition supplements in liquid form.
- Offers diet and wellness products designed for health-conscious consumers.
- Formulates liquid supplements for easy consumption and absorption.
- Markets its products to individuals seeking to improve their overall health and wellness.
- Distributes its supplements through various channels, including online and retail.
How Does EHOS Make Money?
- Develops and manufactures liquid supplements.
- Sells products directly to consumers through online channels.
- Partners with retailers and distributors to expand market reach.
What Industry Does EHOS Operate In?
Ehouse Global, Inc. operates within the global dietary supplements market, which is characterized by increasing consumer awareness of health and wellness. The market includes vitamins, minerals, herbal supplements, and sports nutrition products. Competition is intense, with major players like GBLX and smaller niche brands vying for market share. Ehouse Global's focus on liquid supplements positions it within a specific segment of this market, requiring effective differentiation and marketing strategies to capture consumer attention. The industry is also subject to regulatory scrutiny, requiring companies to comply with labeling and safety standards.
Who Are EHOS's Key Customers?
- Health-conscious individuals seeking convenient supplement options.
- Athletes and fitness enthusiasts looking for performance-enhancing products.
- Individuals with dietary restrictions or specific nutritional needs.
- Consumers seeking to improve their overall health and wellness.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Ehouse Global, Inc. stands at 408.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Ehouse Global, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jonathan Smith. EHOS has traded publicly since 2013.
Financial Health
Ehouse Global, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
EHOS Financials
EHOS Latest News
No recent news available for EHOS.
EHOS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EHOS.
Price Targets
Wall Street price target analysis for EHOS.
EHOS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EHOS; grades run from A+ (80-100) to F (below 30).
Leadership: Jonathan Smith
CEO
Jonathan Smith currently serves as the CEO of Ehouse Global, Inc., managing a small team of two employees. As CEO, Smith is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is crucial for navigating the competitive landscape of the supplement industry and driving the company's growth.
Track Record: Due to the limited information available, it is not possible to assess Jonathan Smith's track record at Ehouse Global, Inc. His tenure and key achievements are currently unknown. Further information is needed to evaluate his impact on the company's performance and strategic direction.
EHOS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ehouse Global, Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or mismanagement is higher on the OTC Other tier.
- Lack of regulatory oversight compared to listed exchanges.
- Difficulty in obtaining reliable information about the company's operations.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Analyze the company's trading volume and liquidity.
- Consult with a qualified financial advisor.
- Company has been in operation since 2003.
- Company has a registered headquarters in San Diego, CA.
- Company engages in the development, production, and sale of liquid supplements.
- Company has a CEO (Jonathan Smith) and a small team of employees.
What Investors Ask About Ehouse Global, Inc. (EHOS) — Healthcare
What does Ehouse Global, Inc. do?
Ehouse Global, Inc. is a biotechnology company that develops, produces, and sells liquid supplements. Its product line includes vitamins, minerals, sports nutrition supplements, and diet and wellness products.
What do analysts say about EHOS stock?
As of March 17, 2026, there is no available analyst coverage for Ehouse Global, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and earnings estimates are not available.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.
- Forward-looking statements are subject to risks and uncertainties.